Micregen’s Board of Directors is composed of highly accomplished individuals with extensive and diverse experience in various fields related to business building, biotech science, and management. They bring a wealth of knowledge and expertise to the table, acquired over many years of working in academia, private and public companies. The Board member’s experience includes leading successful business ventures, working with groundbreaking regenerative biotech research and understanding the intricacies of managing complex organisations.
The Board’s collective experience and professional networks allow them to provide invaluable guidance and leadership to the company, ensuring that Micregen is well-positioned to navigate the challenges and capitalise on the opportunities in today’s rapidly changing business landscape.
Barry Sharples
Non-Executive Director
Over the last 35 years, Barry has founded and managed several technology companies through to sale and IPO.
In 2012 he was treated as a patient at one of the founding scientist's clinics and subsequently began establishing the strategy to take this extraordinary regenerative technology to a global market before formally founding Micregen together in 2015.
Athan Papadopoulos MD
Executive Chairman
A medical doctor who specialised in Biopathology. Over 20 years global biopharmaceutical experience, at a CRO, Novartis, Sanofi and Emergex. Holding international roles as Vice President and Chief Medical Officer.
Athan has headed clinical research and overseen development programs in biologics and immunotherapies. He led development of several important medicines until licensure, and initiated programs that advance the science that is the foundation of medicine.
Steve Ray, PhD
Non-Executive Director
Former Senior Lecturer in Acute & Emergency Care at Oxford Brookes University, Professor of Neuroscience at the Carrick Institute Florida, served as International Scientific Advisor to major South African and Swiss stem cell clinics and cell banks.
Steve has extensive experience in the clinical application of stem cell secretomes that extends over twenty-five years. He has presented over one hundred papers at international scientific conferences, with nineteen as the keynote speaker. He has already translated his research through to proven clinical practice.
Ben Mellows, PhD, BSc
Managing Director
Ben is a biotechnology leader with extensive experience in business development, strategic partnerships, and operational management. As Managing Director of Micregen, he has overseen company strategy, played a central role in investor engagement, as well as the formation of academic and clinical collaborations to advance the company’s proprietary Secretomix® regenerative medicine platform. With a PhD in biomedical science, and an MBA in progress at Henley Business School, Ben combines deep scientific understanding with commercial acumen.
His career has focused on translating Micregen’s innovative Secretomix® science into impactful clinical applications, navigating the complexities of aligning scientific and commercial interests to deliver measurable outcomes.
Robert Mitchell, PhD
Head of Development
Rob obtained his PhD at the University of Reading with his thesis specialising on the regenerative capabilities of the adult stem cell secretome, with a particular emphasis on its effect on skeletal muscle. Rob has worked with Steve and Ketan for over twelve years.Prior to working towards his PhD, Rob worked for a leading life sciences company, developing and manufacturing a wide range of reagents from their constituent materials.
Since 2019 Rob has managed and coordinated Micregen’s clinical manufacturing programme, preparing Micregen’s first therapeutic to enter a combined phase I/II clinical trial in the UK.
Graeme Bell, FCMA, MBA
Independent Director
Graeme is a seasoned biotech CFO and brings over 30 years’ experience, driving growth and value across major biopharmaceutical companies. His experience covers scaling platform-based companies across private and public markets, having helped raise more than $1.5 billion for emerging growth firms. He has held CFO roles at leading life sciences companies including Valo Health, Tmunity, Anacor Pharmaceuticals, and Intellia Therapeutics, and currently also serves as CFO at Owkin. Graeme also held senior executive positions at Merck & Co. Inc., including Global Head of Investor Relations and U.S. Chief Financial Officer. His background combines deep financial expertise with a strong track record in strategic planning, corporate governance, and operational excellence.
At Micregen, Graeme leads the company’s financial strategy and supports commercial negotiations to guide its continued growth.